By Ben Glickman

 

Galapagos said it had entered an agreement with Thermo Fisher Scientific to expand manufacturing of its immune-cell cancer treatment candidate.

The company said that Thermo Fisher had agreed to provide CAR-T manufacturing and kitting services for Galapagos' CAR-T hemato-oncology clinical program in the San Francisco area.

Galapagos in November signed a deal with Landmark Bio to manufacture CAR-T in the Boston area.

 

Write to Ben Glickman at ben.glickman@wsj.com

(END) Dow Jones Newswires

January 04, 2024 16:29 ET (21:29 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.
Thermo Fisher Scientific (NYSE:TMO)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024 Thermo Fisher Scientific 차트를 더 보려면 여기를 클릭.
Thermo Fisher Scientific (NYSE:TMO)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024 Thermo Fisher Scientific 차트를 더 보려면 여기를 클릭.